USTR is confirming earlier reports that there is an agreement in principle on pharmaceutical pricing between the US and UK.
- The deal secured continued UK invested by UK pharmaceutical companies in the US
- Deal will strengthen supply chains a great job in the US.
- Administration is reviewing drug pricing practices of many other US trade partners.
- Deal calls for UK NHS to increase that price it pays for new medicines by 25%.
- US will refrain targeting UK pharmaceutical pricing practices and any future section 301 investigation
